https://doi.org/10.55788/b2c88f06
“Current guidelines recommend fibre supplements as a frontline therapy for constipation, especially for individuals who do not meet the recommended daily fibre intake,” explained Dr Silvia Delgado-Aros (Nestle Health Sciences, Switzerland) [1]. “Although placebo-controlled trials show moderate evidence for the use of soluble fibres in constipation, patients with IBS-associated constipation often have a poor tolerance to these substances.” PHGG is a non-absorbable, water-soluble vegetable fibre that may be better tolerated among these patients.
A double-blind, randomised controlled trial compared the efficacy and safety of PHGG with placebo in adults with functional or IBS-associated chronic constipation. The participants (n=160) received 10 g of PHGG daily or a placebo. The primary endpoint was the frequency of spontaneous bowel movements per week after 6 weeks of therapy.
At week 6, participants in the active arm had a mean increase of 1.57 spontaneous bowel movements per week, compared with 1.14 in the placebo arm (P=0.034), meeting the primary endpoint. The responders' rate, defined as participants who had at least 3 spontaneous bowel movements per week and had an increase of at least 1 over the study period, was also higher in the active arm than in the placebo arm (34.2% vs 17.7%; P=0.018). “In practical terms, the number needed to treat in the active arm was 6,” according to Dr Delgado-Aros.
No serious adverse events (AEs) or discontinuations due to AEs were reported. The AE rates were comparable in the placebo and active arms, with 37.5% and 42.5% of the participants experiencing at least 1 AE, respectively.
“The non-absorbable water-soluble fibre PHGG seems to have a place in the fibre recommendation space for patients with functional or IBS-associated chronic constipation,” concluded Dr Delgado-Aros.
- Buckley MJ, et al. RCT assessing effect of 6-week intervention with 10gr daily dose of partially hydrolyzed guar gum (PHGG) on spontaneous bowel movement frequency in adults with chronic constipation. LB12, UEG Week 2024, 12–15 October, Vienna, Austria.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« How useful is colonoscopy for constipation in young women? Next Article
An accelerated treatment approach may save lives in pancreatic walled-off necrosis »
« How useful is colonoscopy for constipation in young women? Next Article
An accelerated treatment approach may save lives in pancreatic walled-off necrosis »
Table of Contents: UEGW 2024
Featured articles
Cendakimab meets primary endpoints in eosinophilic oesophagitis
IBD: New Drugs, Established Agents, and Prevention
LOVE-CD: Vedolizumab yields better outcomes in early than in late CD
Moving towards the prevention of IBD
New insights into perianal fistulising CD pathogenesis may lead to new therapies
Risankizumab influences key pathogenic Th17 cells in CD
Meaningful corticosteroid-sparing effect of mirikizumab in UC
Extending ustekinumab dosing interval does not influence drug survival in IBD
CULTIVATE: Promising signal for etrasimod in Crohn’s disease
Tamuzimod delivers promising long-term data in UC
TL1A inhibitor tulisokibart shows potential in UC
Upadacitinib associated with normalisation of HRQoL in UC
Pancreas: Improved Diagnostics and Treatment Algorithms
Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA
An accelerated treatment approach may save lives in pancreatic walled-off necrosis
Irritable Bowel Syndrome: from Guar Gum to Tradipitant
Guar gum alleviates IBS-related constipation in a randomised controlled trial
How useful is colonoscopy for constipation in young women?
Liver: Exploring New Therapeutics
Encouraging results for L-carnitine in metabolic dysfunction-associated steatotic liver disease
Other Late-breaking Studies from UEGW
TACITO: Does faecal microbiota transplantation improve survival in mRCC?
Is faecal microbiota transplantation a viable option to treat primary C. difficile infections?
Cendakimab meets primary endpoints in eosinophilic oesophagitis
Related Articles
November 28, 2024
TACITO: Does faecal microbiota transplantation improve survival in mRCC?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
